These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 3078949

  • 21. The c-myc promoter: still MysterY and challenge.
    Wierstra I, Alves J.
    Adv Cancer Res; 2008; 99():113-333. PubMed ID: 18037408
    [Abstract] [Full Text] [Related]

  • 22. Regulation of c-fgr proto-oncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels.
    Sharp NA, Luscombe MJ, Clemens MJ.
    Oncogene; 1989 Aug; 4(8):1043-6. PubMed ID: 2548145
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G, Carpaneto EM, Ponzanelli A, Ulivi M, Millo E, Scarfì S, Roncella S, Benatti U, Boffa LC, Ferrarini M.
    Cancer Res; 2003 Oct 01; 63(19):6144-8. PubMed ID: 14559793
    [Abstract] [Full Text] [Related]

  • 24. Mode of c-myc gene regulation in folic acid-induced kidney regeneration.
    Asselin C, Marcu KB.
    Oncogene Res; 1989 Oct 01; 5(1):67-72. PubMed ID: 2476708
    [Abstract] [Full Text] [Related]

  • 25. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME, Lemieux R, Jung D.
    J Cell Physiol; 2005 Apr 01; 203(1):277-85. PubMed ID: 15468060
    [Abstract] [Full Text] [Related]

  • 26. Effects of IL-3 on promoter usage, attenuation and antisense transcription of the c-myc oncogene in the IL-3-dependent Ba/F3 early pre-B cell line.
    Chang Y, Spicer DB, Sonenshein GE.
    Oncogene; 1991 Nov 01; 6(11):1979-82. PubMed ID: 1682864
    [Abstract] [Full Text] [Related]

  • 27. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT.
    Cancer Res; 1993 Jan 01; 53(1):127-32. PubMed ID: 8416737
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
    Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Bauml G, Rucker O, Schwarzmann F, Wolf H, Minarovits J.
    Med Sci Monit; 2003 Jan 01; 9(1):HY1-9. PubMed ID: 12552250
    [Abstract] [Full Text] [Related]

  • 31. Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression.
    Eick D, Bornkamm GW.
    Nucleic Acids Res; 1986 Nov 11; 14(21):8331-46. PubMed ID: 3537956
    [Abstract] [Full Text] [Related]

  • 32. Distinct mechanisms of c-myc and lymphokine gene expression in an antigen specific T cell clone.
    Heckford SE, Gelmann EP, Matis LA.
    Oncogene; 1988 Oct 11; 3(4):415-21. PubMed ID: 3152599
    [Abstract] [Full Text] [Related]

  • 33. In situ and in vitro evidence for intragenic binding of nuclear factors at the murine c-myc locus.
    Tourkine N, Mechti N, Piechaczyk M, Jeanteur P, Blanchard JM.
    Oncogene; 1989 Aug 11; 4(8):973-8. PubMed ID: 2548146
    [Abstract] [Full Text] [Related]

  • 34. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
    Gutsch DE, Marcu KB, Kenney SC.
    Cell Mol Biol (Noisy-le-grand); 1994 Sep 11; 40(6):747-60. PubMed ID: 7812182
    [Abstract] [Full Text] [Related]

  • 35. ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
    Ben-Yosef T, Yanuka O, Benvenisty N.
    Oncogene; 1996 Nov 07; 13(9):1859-66. PubMed ID: 8934531
    [Abstract] [Full Text] [Related]

  • 36. Expression of normal and translocated c-myc alleles in Burkitt's lymphoma cells: evidence for different regulation.
    Eick D, Bornkamm GW.
    EMBO J; 1989 Jul 07; 8(7):1965-72. PubMed ID: 2551669
    [Abstract] [Full Text] [Related]

  • 37. Decreased steady state c-myc mRNA in activated T cell cultures from old humans is caused by a smaller proportion of T cells that transcribe the c-myc gene.
    Gamble DA, Schwab R, Weksler ME, Szabo P.
    J Immunol; 1990 May 01; 144(9):3569-73. PubMed ID: 2184192
    [Abstract] [Full Text] [Related]

  • 38. Expression of a transfected human c-myc oncogene inhibits differentiation of a mouse erythroleukaemia cell line.
    Dmitrovsky E, Kuehl WM, Hollis GF, Kirsch IR, Bender TP, Segal S.
    Nature; 1990 May 01; 322(6081):748-50. PubMed ID: 3528861
    [Abstract] [Full Text] [Related]

  • 39. c-myc Suppression in Burkitt's lymphoma cells.
    Simonsson T, Henriksson M.
    Biochem Biophys Res Commun; 2002 Jan 11; 290(1):11-5. PubMed ID: 11779125
    [Abstract] [Full Text] [Related]

  • 40. Loss of transcriptional attenuation in N-myc is associated with progression towards a more malignant phenotype.
    Xu L, Meng Y, Wallen R, DePinho RA.
    Oncogene; 1995 Nov 02; 11(9):1865-72. PubMed ID: 7478616
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.